Courtney D. DiNardo, MD, MSCE

Courtney DiNardo, MD, concludes with discussing some challenges faced when treating patients with AML and shares some advice for community oncologists treating acute myeloid leukemia.

A review of the safety outcome data of venetoclax plus azacitidine from the VIALE-A trial.

Dr Courtney DiNardo details the dosing recommendations for venetoclax plus azacitidine and the importance of bone marrow assessments.

Dr Courtney DiNardo reviews the efficacy data from the VIALE-A trial and explains the rationale for combining venetoclax with azacitidine as a treatment option for patients with AML.

Courtney DiNardo, MD, describes how the treatment options for patients with newly diagnosed acute myeloid leukemia differs for patients under and over 60 years of age.

Courtney D. DiNardo, MD, discusses the current treatment landscape for patients with IDH1-mutated acute myeloid leukemia and how potential doublet and triplet combinations may play a role in this setting.

Courtney D. DiNardo, MD, MSCE, discusses what is on the horizon for the acute myeloid leukemia setting.

Courtney D. DiNardo, MD, MSCE, explains the rationale for the phase II AG221-AML-005 trial.